Two staff investigators are proposed. Each has a distinct function and role coordinating unique activities that are not covered by other leadership positions in the Case CCC nor otherwise supported by the CCSG. Jill Barnholtz-Sloan, PhD, an expert in biostatistics and bioinformatics with a special interest in cancer genomics with links to clinical annotation, is spearheading the integration of annotated data sets across the Cancer Center and its consortium sites. She has a unique skill set in overcoming institutional barriers to collaborative efforts especially as it relates to clinical informatics for research. Her role as staff investigator will be to promote such activities across scientific programs, clinical research activities and sites, and to facilitate enhanced collaborative investigations. Yogen Saunthararajah, MD has developed strong collaborative efforts in the areas of drug discovery and drug development through his interest in targeted therapeutics. He is a member of the Hematopoietic Disorders and Developmental Therapeutics Programs where he has successfully developed new drugs that target myeloid malignancy differentiation through demethylation. In his role as staff investigator, he will further coordinate drug discovery and development of investigators across scientific programs and provide the interface from the basic laboratories to clinical investigation. In so doing, he will facilitate multiinvestigator interactions and grant applications. He will partner with Afshin Dowlati, MD, Director of the Center for Cancer Drug Development at CWRU, to provide closer interface with Cleveland Clinic colleagues and scientists.
The Case Comprehensive Cancer Center is Northeast Ohio's only NCI designated comprehensive cancer center providing bench-to-bedside medical research involving partnerships between basic, clinical and population scientists to speed translation of laboratory discoveries into new prevention/intervention and cancer treatments.
|Levinson, Kimberly L; Jernigan, Amelia M; Flocke, Susan A et al. (2016) Intimate Partner Violence and Barriers to Cervical Cancer Screening: A Gynecologic Oncology Fellow Research Network Study. J Low Genit Tract Dis 20:47-51|
|Cooper, Gregory S; Kou, Tzuyung D; Schluchter, Mark D et al. (2016) Changes in Receipt of Cancer Screening in Medicare Beneficiaries Following the Affordable Care Act. J Natl Cancer Inst 108:|
|Wiechert, Andrew; Saygin, Caner; Thiagarajan, Praveena S et al. (2016) Cisplatin induces stemness in ovarian cancer. Oncotarget 7:30511-22|
|Somasegar, Sahana; Li, Li; Thompson, Cheryl L (2016) No association of reproductive risk factors with breast cancer tumor grade. Eur J Cancer Prev :|
|Kenyon, Jonathan; Nickel-Meester, Gabrielle; Qing, Yulan et al. (2016) Epigenetic Loss of MLH1 Expression in Normal Human Hematopoietic Stem Cell Clones is Defined by the Promoter CpG Methylation Pattern Observed by High-Throughput Methylation Specific Sequencing. Int J Stem Cell Res Ther 3:|
|Dowlati, A; Lipka, M B; McColl, K et al. (2016) Clinical correlation of extensive-stage small-cell lung cancer genomics. Ann Oncol 27:642-7|
|Markowitz, Sanford D; Nock, Nora L; Schmit, Stephanie L et al. (2016) A Germline Variant on Chromosome 4q31.1 Associates with Susceptibility to Developing Colon Cancer Metastasis. PLoS One 11:e0146435|
|Wang, Y; Deng, O; Feng, Z et al. (2016) RNF126 promotes homologous recombination via regulation of E2F1-mediated BRCA1 expression. Oncogene 35:1363-72|
|Doherty, Mary R; Smigiel, Jacob M; Junk, Damian J et al. (2016) Cancer Stem Cell Plasticity Drives Therapeutic Resistance. Cancers (Basel) 8:|
|Blum, Andrew E; Venkitachalam, Srividya; Guo, Yan et al. (2016) RNA Sequencing Identifies Transcriptionally Viable Gene Fusions in Esophageal Adenocarcinomas. Cancer Res 76:5628-5633|
Showing the most recent 10 out of 1148 publications